EXCLUSIVE: EMA looks into Indian clinical trials following NIH halts
This article was originally published in Scrip
Executive Summary
Following recent reports that the US government had stopped clinical trials it was sponsoring in India due to concerns over new regulations in the country, the European Medicines Agency has confirmed that it has "approached the Indian drug controller to learn more about these issues and any possible implication on trials to be included in European applications."
You may also be interested in...
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.
Quotable: Top Experts On Policy Hot Topics
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.